Publication Topic

Robison TW. 2011. Dealing with positive in vitro mammalian cell genotoxicity assays. Inter Drug Discovery 6(5):40-43.

Robison TW. Genotoxic impurity guidance – Current experiences, FDA perspective. USP Annual Meeting, New Orleans, LA, December 2010.

Robison TW. Dealing with positive in vitro mammalian cell genotoxicity assays. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.

Robison TW. Dealing with genotoxic impurities from a regulatory perspective. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.

Robison TW. Assessing genotoxic impurities. DIA Meeting (Early drug development: Navigating the treacherous rapids). Bethesda, MD, October 2010

Waters MD, Jackson MA, Lea IA. 2010. Characterizing and predicting carcinogenicity and mode-of-action using conventional and toxicogenomics methods. Mutat Res 705(3):184–200; doi: 10.1016/j.mrrev.2010.04.005.

Elespuru RK, Agarwal R, Atrakchi A, Bigger CAH, Heflich RH, Jagannath D, Levy DD…Robison TW, et al. 2009. Current and future application of genetic toxicity assays: The role and value of in vitro mammalian assays. Toxicol Sci 109(2):172-179; doi: 10.1093/toxsci/kfp067.

Peters JM, Aoyama T, Burns AM, Gonzalez FJ. 2003. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: Studies using null mice. Biochim Biophys Acta 1632(1-3):80-89; doi: 10.1016/s1388-1981(03)00065-9. PMID: 12782154.

Schmitt D, Frankos V, Westland J, Zoetis T. 1991. Toxicologic evaluation of cellulon fiber; Genotoxicity, pyrogenicity, acute and subchronic toxicity. J Am Coll Toxicol 10(5):541–554; doi: 10.3109/109158191090786.